Isolation of HIV Antibodies Advances Search For AIDS Vaccine
A team of researchers has “identified 17 potent antibodies whose discovery opened up valuable pathways in the search for an AIDS vaccine,” Agence France-Presse reports (8/17). The researchers “at and associated with the International AIDS Vaccine Initiative (IAVI), the Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, report in the current issue of Nature” that the antibodies are “capable of neutralizing a broad spectrum of variants of HIV, the virus that causes AIDS,”Â according to a jointÂ press releaseÂ (8/17).
IAVI “said the quest for HIV-neutralizing antibodies was ‘perhaps the greatest challenge’ facing vaccine engineers,” AFP writes (8/17). Wayne Koff, chief scientific officer for IAVI, “said the problem with HIV is that it’s a hyper-variable virus,” meaning that the virus, which “has millions of strains,” is “different all over the world,” making broadly neutralizing antibodies necessary for a vaccine that will work worldwide, VOA News reports (DeCapua, 8/17).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.